In this study, 17 critically ill patients with H7N9-induced ARDS received multiple intravenous administrations of menstrual blood-derived cells (106 cells per infusion in Plasmalyte) obtained from a single healthy donor and outcomes were compared to 44 comparably critically ill patients receiving standard antiviral and supportive therapies.